RE:RE:RE:RE:RE:RE:RE:How do we determine fair market cap from a licensing deal?The big problem here is time. I don't want to hold the stock for 10 years while all this potentially plays out or falls apart. Any short term pop and my paper will be hitting the street hard and heavy.
MoneyMouth wrote:
I agree, I think knowing your value is very important. If i created an amazing product but only sold it for 50 cents people would think its just cheap shiiit. But preclinical trials are expensive and perhaps adding on a price tag to try out an experimental product is unappealing to large pharma. The risk could be too high. By letting them try before they buy, minimizes the risk on their end and also opens up the door for creating strong relationships with those companies. If they bought before they tried and it failed then the door potentially closes. They may not want to have to keep purchasing the pouch to test all of the different trial parameters to find the right solution. It may not be lucrative now, but I've even seen you argue in favor of multiple collaborations rather than getting into bed with one pharma exclusively and thats because the most important thing right now is keeping the door open for everyone.
The other thing you are not considering is that there are many different licensing avenues throughout the entire cell pouch pipeline. They could license out manufacturing rights, distribution rights, cell manufacturing for each treatment, manufacturing for immune protection tech, patent usage, the usage of the pouch itself, they could bundle up a combination of these things as well. They could also region lock these licenses for geographic exclusivity. You are very narrow minded when it comes to licensing potential, you seem to think they can only license a complete package product as if you could only license a syringe if it contained a flu shot.